Analysis updated on Oct. 13, 2026 (UTC) · Alpha · vs marketSwitch to Total · NYSE
On Oct. 13, 2026, CRL is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 5379 stocks scored that day.
Charles River Laboratories International, Inc. is a large-cap company with a market capitalization of $14.27B. It ranks number 4 by market capitalization among the 12 Services-Commercial Physical & Biological Research issuers in our coverage with a current forecast.
A per-ticker accuracy statistic for CRL is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.3%, buy ≥ +0.5%, sell < -0.5%, strong sell < -1.6% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-13 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, CRL included.
Follow CRL free90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Services-Commercial Physical & Biological Research peers listed below that report each metric.
| Metric | CRL | Rank |
|---|---|---|
| Market Cap | $14.27B | 4/12 |
| P/B Ratio | 5.03x | 4/8 |
| EPS | $-4.00 | – |
| Book Value/Share | $59.48 | – |
| Revenue/Share | $83.77 | – |
| FCF/Share | $7.76 | – |
| Metric | CRL | Rank |
|---|---|---|
| ROE | -8.4% | 5/10 |
| ROA | -3.2% | 5/13 |
| ROIC | 1.4% | 8/12 |
| Operating Margin | 2.2% | 6/13 |
| Net Margin | -6.0% | 5/11 |
| EBT Margin | -0.9% | 6/13 |
| Tax Rate | -152.4% | – |
The effective tax rate is outside the normal band, which points to a large non-recurring tax item in the trailing twelve months; headline net income, net margin and P/E are affected by it.
| Metric | CRL | Rank |
|---|---|---|
| Current Ratio | 1.35x | 6/16 |
| Quick Ratio | 1.04x | 5/6 |
| D/E Ratio | 1.64x | 5/11 |
| Financial Leverage | 2.65x | 5/11 |
| Interest Coverage | 5.0x | 4/13 |
| Working Capital | $394M | 2/15 |
| Metric | CRL | Rank |
|---|---|---|
| Operating Cash Flow | $582M | 5/15 |
| Free Cash Flow | $371M | 3/7 |
| Capital Spending | -$212M | 6/7 |
| OCF Growth YoY | -26.1% | 5/5 |
| FCF Growth YoY | -35.9% | – |
| FCF/Sales | 9.3% | 4/8 |
| CapEx/Sales | 5.3% | 3/8 |
| Metric | CRL | Rank |
|---|---|---|
| Asset Turnover | 0.53x | 6/9 |
| Receivables Turnover | 5.6x | 4/7 |
| Fixed Assets Turnover | 2.7x | 7/9 |
| Days Sales Outstanding | 65 days | 4/7 |
| Metric | CRL | Rank |
|---|---|---|
| Total Revenue | $4.00B | 3/8 |
| Operating Income | $90M | 5/15 |
| Net Income | -$238M | 13/13 |
| SG&A Expense | $762M | 4/12 |
| Metric | CRL | Rank |
|---|---|---|
| Shares Outstanding | 48M | – |
| Total Current Assets | $1.53B | 20.3% of assets |
| Cash & Short-term Investments | $192M | 2.5% of assets |
| Accounts Receivable | $712M | 9.4% of assets |
| Inventory | $346M | 4.6% of assets |
| Total Liabilities | $4.64B | 61.7% of assets |
| Short-term Debt | $994M | 13.2% of assets |
Companies classified under the same SEC industry code as Charles River Laboratories International, Inc. (Services-Commercial Physical & Biological Research): 16 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| CRL Charles River Laboratories International, Inc. | ▶ | $14.27B |
| IQV Iqvia Holdings Inc. | ▼ | $43.51B |
| INCY Incyte Corp | ▼ | $21.70B |
| MEDP Medpace Holdings, Inc. | ▶ | $17.02B |
| ICLR Icon Plc | ▶ | $12.68B |
| ABSI Absci Corp | ▲ | $1.56B |
| OABI Omniab, Inc. | ▲ | $683M |
| NRC Nrc Health | ▲ | $446M |
| MXCT Maxcyte, Inc. | ▲ | $100M |
| ONMD Onemednet Corp | ▶ | $23M |
| VSBC Vitaspring Biomedical Co. Ltd. | ▼ | $7M |
| BUDZ Weed, Inc. | ▲ | $3M |
| BIAF Bioaffinity Technologies, Inc. | ▼ | N/A |
| CBIH Cannabis Bioscience International Holdings, Inc. | ▼ | N/A |
| FOXO Foxo Technologies Inc. | ▼ | N/A |
| ISPC Ispecimen Inc. | ▼ | N/A |
Charles River Laboratories International, Inc. and Magellan Stem Cells announced their collaboration to support Magellan in the development and clinical advancement of its proprietary stem cell-based ...
Charles River Laboratories International (CRL) and digital solution provider Autolomous have launched Apollo Orchestrate™, a digital laboratory execution capability integrated into Charles River's ...
Ladies and gentlemen, thank you for standing by, and welcome to the Charles River Laboratories First Quarter 2026 Earnings Conference Call. This call is being recorded. [Operator Instructions] I would ...
On Oct. 13, 2026, CRL is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 5379 stocks scored that day.
A per-ticker accuracy statistic for CRL is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Charles River Laboratories International, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 13, 2026.
16 issuers in our coverage, CRL included, share the SEC industry code Services-Commercial Physical & Biological Research. The largest are: Iqvia Holdings Inc. (IQV), Incyte Corp (INCY), Medpace Holdings, Inc. (MEDP), Icon Plc (ICLR), Absci Corp (ABSI), Omniab, Inc. (OABI).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.
Signals, companies, plans: answered from live data.
I read Intratio's daily model signals, company data and your account to answer in seconds, in your language.